Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-09-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于公司第一期员工持股计划即将届满的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (853 characters) from a company's board about the nearing expiration of an employee stock ownership plan. It provides details about the plan's duration, shares purchased, and current holdings. There is no financial statement, no detailed report, and no mention of a full report being attached or published. The content is an update on a capital-related employee share plan nearing maturity, which fits best under Capital/Financing Update (CAP). It is not a full report, nor a regulatory filing or announcement of a report publication. Therefore, the classification is CAP with high confidence.
2017-09-29 Chinese
关于对上海证券交易所问询函回复的公告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed response from the company 中源协和细胞基因工程股份有限公司 to an inquiry letter from the Shanghai Stock Exchange regarding the company's 2017 semi-annual report (half-year report). It addresses specific questions about business operations, financial performance, goodwill impairment testing, sales and management expenses, guarantees to related parties, and bad debt provisions. The document includes detailed financial data, explanations of changes in business and accounting treatments, and auditor opinions on the matters discussed. The content is focused on clarifying and supplementing disclosures made in the company's 2017 interim (half-year) report, which is consistent with a regulatory inquiry response related to an interim report. The document length (7622 characters) and detailed financial data indicate it is not a brief announcement but a substantive reply. Therefore, the document is best classified as an Interim / Quarterly Report (IR) type filing, as it contains comprehensive financial data and analysis for a period shorter than a full fiscal year, specifically the 2017 half-year period. H1 2017
2017-09-27 Chinese
2017年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the company's 2017 fourth extraordinary general meeting of shareholders, including voting results, attendance, and legal witness statements. It contains no financial statements or management discussion but focuses on shareholder meeting decisions and voting outcomes. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and it is not a report publication or regulatory filing. Therefore, the classification is DVA with high confidence.
2017-09-27 Chinese
2017年第四次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedures of a company's 2017 fourth extraordinary general meeting of shareholders. It details the convening, attendance, voting procedures, and results of the meeting. The document does not contain financial statements or performance data but focuses on the validation of the shareholder meeting process and voting outcomes. It is not an announcement of voting results per se, but a legal opinion on the meeting's compliance and validity. Given the nature of the document as a legal opinion on a shareholder meeting, it best fits under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2017-09-27 Chinese
瑞华会计师事务所关于上海证券交易所《关于对中源协和2017年半年度报告的事后审核问询函》的回复
Regulatory Filings
2017-09-27 Chinese
关于延期回复上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company regarding a delay in responding to an inquiry letter from the Shanghai Stock Exchange about the company's 2017 half-year report. It does not contain any financial data or the report itself, but rather informs about the postponement of the reply. The length is only 496 characters, indicating it is a brief announcement. According to the rules, such a document is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2017-09-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.